Thus, short‐term CSF1R inhibition resulting in reduced NLRP3 inflammasome complexes in residual microglia in the early stage of AD, along with an overall reduction in concentrations of NLRP3 inflammasome activation mediators and end products observed in this study, promises to maintain better brain function for extended periods. This evidence concerns the gene NLRP3 and Alzheimer disease.